Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,861 matching trials from the live ClinicalTrials.gov search.
Filters: Chapel Hill, North Carolina Clear all
Active, not recruiting Phase 2Phase 3 Interventional

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
62
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 1:18 PM EDT
Completed No phase listed Observational

Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management

NCT02075905
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Adenocarcinoma, Intestinal Metaplasia, Dysplasia
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 30, 2026, 1:18 PM EDT
Completed No phase listed Observational

Immuno-Oncology Database and Bioregistry

NCT04656873
View directory record Official record
Conditions
Malignancy, Immune System Diseases, Autoimmune Diseases
Interventions
Biospecimen Collection, Medical Chart Review, Questionnaires/Surveys
Procedure · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 30, 2026, 1:18 PM EDT
Completed Phase 4 Interventional Results available

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 30, 2026, 1:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
15
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 1:18 PM EDT
Completed No phase listed Observational

Hemophilia Inhibitor Previously Untreated Patient Study

NCT01652027
View directory record Official record
Conditions
Hemophilia A
Interventions
FVIII concentrate
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
13
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Lexington, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 1:18 PM EDT
Active, not recruiting Phase 1 Interventional

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

NCT04960579
View directory record Official record
Conditions
Multiple Myeloma
Interventions
P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2042
U.S. locations
23
States / cities
Goodyear, Arizona • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 30, 2026, 1:18 PM EDT
Withdrawn Phase 4 Interventional

Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine

NCT06784180
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Morphine, Bupivacaine, Fentanyl, Hydromorphone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 30, 2026, 1:18 PM EDT
Withdrawn Phase 3 Interventional

A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

NCT02974322
View directory record Official record
Conditions
Crohn Disease
Interventions
GED-0301, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
136
States / cities
Litchfield Park, Arizona • Mesa, Arizona • Phoenix, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 30, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT00733746
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
erlotinib hydrochloride, gemcitabine hydrochloride, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 30, 2026, 1:18 PM EDT
Terminated Not applicable Interventional

A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy

NCT01845454
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
trūFreeze™ Spray Cryotherapy
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Jacksonville, Florida • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 30, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

NCT04712669
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
28
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 30, 2026, 1:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing the Efficacy of a Spousal Support Enhanced Weight Loss Program on Weight Loss Among African American Men

NCT02458053
View directory record Official record
Conditions
Overweight, Weight Loss, Obese
Interventions
Attends with partner, Couples Skill Training, Face to face group sessions, Self Monitor, Notebook, Feedback
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 30, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

NCT00818441
View directory record Official record
Conditions
Carcinoma, Non-small Cell
Interventions
Dacomitinib (PF-00299804)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
31
States / cities
Orange, California • Pleasant Hill, California • Salinas, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 30, 2026, 1:18 PM EDT
Withdrawn No phase listed Observational

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

NCT01831037
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 30, 2026, 1:18 PM EDT
Completed Not applicable Interventional Results available

HEMOBLAST Pivotal Clinical Investigation

NCT02780869
View directory record Official record
Conditions
Hemostasis
Interventions
HEMOBLAST Bellows, Absorbable gelatin sponge, USP with thrombin
Device
Lead sponsor
Biom'Up France SAS
Industry
Eligibility
21 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Oct 30, 2026, 1:18 PM EDT
Recruiting No phase listed Observational

ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA

NCT05004051
View directory record Official record
Conditions
Abdominal Aortic Aneurysms
Interventions
ViTAA Analysis
Device
Lead sponsor
ViTAA Medical Solutions
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 30, 2026, 1:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)

NCT07634653
View directory record Official record
Conditions
Leukemia, Acute Leukemia, Acute Lymphoid Leukemia, Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Exercises
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
6 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 30, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

NCT02611817
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab SC 108 mg, Placebo, Vedolizumab IV 300 mg
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Hamden, Connecticut • Middletown, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 30, 2026, 1:18 PM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of Primary Sampling Scatter Correction for Chest Tomosynthesis

NCT04076696
View directory record Official record
Conditions
Pulmonary Nodule, Solitary, Pulmonary Nodule, Multiple
Interventions
Scatter corrected s-DCT
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 30, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer

NCT00006110
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, conventional surgery
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
1 Year to 120 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 30, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03248882
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Placebo, PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
60
States / cities
Bakersfield, California • Chula Vista, California • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 30, 2026, 1:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

NCT06687603
View directory record Official record
Conditions
Barrett Esophagus, Gastroesophageal Reflux, Esophageal Adenocarcinoma
Interventions
EsoCheck, EsoGuard
Device · Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
50 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 1:18 PM EDT
Completed No phase listed Observational

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

NCT00003096
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
DNA ploidy analysis, comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization
Genetic
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
56
States / cities
Phoenix, Arizona • Downey, California • Loma Linda, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 30, 2026, 1:18 PM EDT